The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma

被引：41

作者：

Inoda, Satoko ^{[1
,2
]}

Morita, Rena ^{[1
,6
]}

Hirohashi, Yoshihiko ^{[1
]}

Torigoe, Toshihiko ^{[1
]}

Asanuma, Hiroko ^{[3
]}

Nakazawa, Emiri ^{[4
]}

Nakatsugawa, Munehide ^{[1
]}

Tamura, Yasuaki ^{[1
]}

Kamiguchi, Kenjiro ^{[1
]}

Tsuruma, Tetsuhiro ^{[2
]}

Terui, Takeshi ^{[5
]}

Ishitani, Kunihiko ^{[5
]}

Hashino, Satoshi ^{[6
]}

Wang, Qiang ^{[7
,8
]}

Greene, Mark I. ^{[7
,8
]}

Hasegawa, Tadashi ^{[3
]}

Hirata, Koichi ^{[2
]}

Asaka, Masahiro ^{[6
]}

Sato, Noriyuki ^{[1
]}

机构：

[1] Sapporo Med Univ, Sch Med, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[2] Sapporo Med Univ, Sch Med, Dept Surg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[3] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan

[4] Japan Sci & Technol Agcy, Kita Ku, Sapporo, Hokkaido 0600819, Japan

[5] Higashi Sapporo Hosp, Shiroishi Ku, Sapporo, Hokkaido 0038585, Japan

[6] Hokkaido Univ, Dept Gastroenterol & Hematol, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan

[7] Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA

[8] Univ Penn, Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA

来源：

EXPERIMENTAL AND MOLECULAR PATHOLOGY | 2011年 / 90卷 / 01期

关键词：

Cep55/c10orf3; HLA-A24; Colorectal carcinoma; CTL; Tumor antigen; PROTEIN; CENTROSOME; TUMOR; CYTOKINESIS; MIDBODY; CEP55; CELLS;

D O I：

10.1016/j.yexmp.2010.10.001

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

In our previous study, we demonstrated that a peptide derived from the novel centrosome residing protein Cep55/c10orf3 can be targeted by the cytotoxic T lymphocytes (CTLs) in peripheral blood mononuclear cells (PBMCs) of breast carcinoma patients. In this report, we evaluated the feasibility of cancer immunotherapy using Cep55/c10orf3 peptide for colorectal carcinoma (CRC). To evaluate the expression of Cep55/c10orf3 in CRC tissues, we performed immunohistochemical staining of using anti-Cep55/c10orf3 monoclonal antibody. Sixty-three percent cases showed weak positive for Cep55/c10orf3 in total 70 CRC cases. The Cep55/c10orf3 expression intention was collated with high histological grade of CRC. Thus, we hypothesized that Cep55/c10orf3 can also be the target of CTLs in CRC cases. We generated CTLs from PBMCs of human leukocyte antigen (HLA)-A24-positive colorectal carcinoma patients using HLA-A24-restricted Cep55/c10orf3 peptides. Two of 6 colorectal cancer patients were reactive for the Cep55/c10orf3_193(10) peptide, which was the only immunogenic peptide in breast carcinoma patients. CTL clone specific for Cep55/c10orf3_193(10) recognized and lysed HLA-A24 (+) and Cep55/c10orf3 (+) colorectal carcinoma cell lines. In addition, 1 of 6 colorectal carcinoma patients was reactive for the Cep55/c10orf3_402(11) and Cep55/c10orf3_283(12) peptides, but not for Cep55/c10orf3_193(10) with the ELISPOT assay. These observations suggest that the antigenic peptide repertoire presented by HLA-A24 in colorectal carcinoma might be different from that in breast carcinoma. Thus, these peptide vaccination peptide mixture of Cep55/c10orf3_193(10). Cep55/c10orf3_402(11) and Cep55/c10orf3_283(12) might be more effective than a single peptide in the treatment of colorectal carcinoma patients. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：55 / 60

页数：6

共 11 条

[1] Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis [J].

Fabbro, M ;

Zhou, BB ;

Takahashi, M ;

Sarcevic, B ;

Lal, P ;

Graham, ME ;

Gabrielli, BG ;

Robinson, PJ ;

Nigg, EA ;

Ono, Y ;

Khanna, KK .

DEVELOPMENTAL CELL, 2005, 9 (04) :477-488

[2]

Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731

[3] The functioning antigens: beyond just as the immunological targets [J].

Hirohashi, Yoshihiko ;

Torigoe, Toshihiko ;

Inoda, Satoko ;

Kobayasi, Jun-ichi ;

Nakatsugawa, Munehide ;

Mori, Takashi ;

Hara, Isao ;

Sato, Noriyuki .

CANCER SCIENCE, 2009, 100 (05) :798-806

[4] Cep55/c10orf3, a Tumor Antigen Derived From a Centrosome Residing Protein in Breast Carcinoma [J].

Inoda, Satoko ;

Hirohashi, Yoshihiko ;

Torigoe, Toshihiko ;

Nakatsugawa, Munehide ;

Kiriyama, Kenji ;

Nakazawa, Emiri ;

Harada, Kenji ;

Takasu, Hideo ;

Tamura, Yasuaki ;

Kamiguchi, Kenjiro ;

Asanuma, Hiroko ;

Tsuruma, Tetsuhiro ;

Terui, Takeshi ;

Ishitani, Kunihiko ;

Ohmura, Tosei ;

Wang, Qiang ;

Greene, Mark I. ;

Hasegawa, Tadashi ;

Hirata, Koichi ;

Sato, Noriyuki .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (05) :474-485

[5]

KONDO A, 1995, J IMMUNOL, V155, P4307

[6] Plat-E: an efficient and stable system for transient packaging of retroviruses [J].

Morita, S ;

Kojima, T ;

Kitamura, T .

GENE THERAPY, 2000, 7 (12) :1063-1066

[7] Aurora-A kinase: a novel target of cellular immunotherapy for leukemia [J].

Ochi, Toshiki ;

Fujiwara, Hiroshi ;

Suemori, Koichiro ;

Azuma, Taichi ;

Yakushijin, Yoshihiro ;

Hato, Takaaki ;

Kuzushima, Kiyotaka ;

Yasukawa, Masaki .

BLOOD, 2009, 113 (01) :66-74

[8] Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor [J].

Sakai, M ;

Shimokawa, T ;

Kobayashi, T ;

Matsushima, S ;

Yamada, Y ;

Nakamura, Y ;

Furukawa, Y .

ONCOGENE, 2006, 25 (03) :480-486

[9]

SATO T, 1986, CANCER RES, V46, P4384

[10] The centrosome in normal and transformed cells [J].

Wang, Q ;

Hirohashi, Y ;

Furuuchi, K ;

Zhao, HW ;

Liu, QD ;

Zhang, HT ;

Murali, R ;

Berezov, A ;

Du, XL ;

Li, B ;

Greene, MI .

DNA AND CELL BIOLOGY, 2004, 23 (08) :475-489

← 1 2 →